| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Material Impairments, Departure of Directors or Certain Officers; Election ... |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/03/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| 683 Capital Management, LLC reports a 4.5% stake in SQZ Biotechnologies Company |
| 02/14/2023 |
SC 13G/A
| AMERICAN INTERNATIONAL GROUP, INC. reports a 8.5% stake in SQZ Biotechnologies Company |
| 02/14/2023 |
SC 13G/A
| NanoDimension II Management Ltd reports a 4.9% stake in SQZ biotechnologies company |
| 01/26/2023 |
4
| Capasso Richard (See Remarks) has filed a Form 4 on SQZ Biotechnologies Co|
Txns:
| Granted 213,000 options
@ $0.73, valued at
$155.5k
|
|
| 01/26/2023 |
4
| Warren Marshelle Smith (Chief Medical Officer) has filed a Form 4 on SQZ Biotechnologies Co|
Txns:
| Granted 261,000 options
@ $0.73, valued at
$190.5k
|
|
| 01/26/2023 |
4
| Knopf Lawrence J (General Counsel) has filed a Form 4 on SQZ Biotechnologies Co|
Txns:
| Granted 227,000 options
@ $0.73, valued at
$165.7k
|
|
| 01/26/2023 |
4
| First David (Chief People Officer) has filed a Form 4 on SQZ Biotechnologies Co|
Txns:
| Granted 200,000 options
@ $0.73, valued at
$146k
|
|
| 01/26/2023 |
4
| BERNSTEIN HOWARD PHD MD (Interim Chief Executive Office) has filed a Form 4 on SQZ Biotechnologies Co|
Txns:
| Granted 830,000 options
@ $0.73, valued at
$605.9k
|
|
| 01/18/2023 |
8-K
| Quarterly results |
| 12/06/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/06/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"SQZ Biotechnologies Announces Leadership Transition Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company’s Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering WATERTOWN, Mass., September 6, 2022 –" |
|
| 08/16/2022 |
4
| Capasso Richard (See Remarks) has filed a Form 4 on SQZ Biotechnologies Co|
Txns:
| Sold 1,183 shares
@ $3.3262, valued at
$3.9k
|
|
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/11/2022 |
8-K
| Quarterly results |
| 07/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2022 |
4
| Capasso Richard (See Remarks) has filed a Form 4 on SQZ Biotechnologies Co|
Txns:
| Granted 1,183 shares
@ $2.703, valued at
$3.2k
|
|
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|